Mmmm.
Britain's leading drug companies are holding firm against the wave of mergers sweeping the industry in America. David Brennan, the boss of AstraZeneca, said this week that he saw no need to join the latest round of deals. His focus would be on collaboration rather than consolidation.
Andrew Witty takes a similar line at the rival GlaxoSmithKline and yesterday he unveiled an HIV drug joint venture with Pfizer that could be a blueprint for collaboration in the future.
1 comment:
Nope. But Pfizer and GSK, yes. Pfizer uses "collaboration" as a preliminary way of sounding out merger/takeover candidates. GSK is way too big for Pfizer to swallow in one go, but watch out for a piecemeal expansion of these so-called collaborations...
Post a Comment